Introduction

Dr. Gil Rabinovich is a neurologist and dementia expert at the University of California, San Francisco. He was also a co-author of an editorial published in JAMA that accompanied the Trailblazer All2 trial. Denanamab is one of several different monoclonal antibodies that all target beta amyloid. The idea is that if you can remove a beta from the brain using an antibody approach, you can slow down this cascade of events.